Liopcomb

Ezetimibe and Rosuvastatin, the active ingredients in Liopcomb, are a combination lipid‑lowering agent presented as a tablet for oral use. It treats primary hypercholesterolemia, mixed dyslipidemia and helps reduce cardiovascular risk in adults. GNH USA supplies Liopcomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liopcomb is a fixed‑dose combination that targets lipid abnormalities and cardiovascular risk. Primary hypercholesterolemia: lowers LDL‑C to achieve guideline‑recommended targets. Mixed dyslipidemia: improves overall lipid profile including LDL‑C, triglycerides and HDL‑C. Prevention of cardiovascular events in high‑risk patients: reduces incidence of myocardial infarction, stroke and related complications.

Common Side Effects: - Headache - Abdominal pain - Diarrhea - Myalgia - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy - Significant hepatic injury - Allergic reactions such as angioedema or Stevens‑Johnson syndrome - Severe muscle breakdown with elevated CK - Hepatic failure

Before initiating Liopcomb, consider the following precautions. Liver function monitoring: assess baseline and periodic ALT/AST levels. Renal impairment: evaluate kidney function and adjust if severe. Pregnancy and lactation: avoid unless benefits outweigh potential risks. Drug interactions: review concomitant medications, especially CYP3A4 inhibitors. Muscle symptoms: discontinue if severe myopathy occurs. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Liopcomb may interact with several medicines that affect its safety or efficacy. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase rosuvastatin exposure. - Cyclosporine: markedly raises rosuvastatin levels. - Gemfibrozil: increased risk of myopathy. Moderate Interactions (Monitor Closely): - Niacin: may increase liver enzyme elevations. - Warfarin: may enhance anticoagulant effect; monitor INR.